ConductScience.org, home

Paper1345950

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Lancet, 1992. Cited by 358 papers, by iCite.

Cite this record

ConductScience Library. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Papers, record 1345950. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1345950

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
PubMed
Journal
Lancet
PubMed
Year
1992
PubMed
Publication types
Comparative Study, Journal Article, Review
PubMed
Citations, by iCite
358
iCite
Relative citation ratio, by iCite
10.6
iCite
Revised in PubMed
2022-03-11
PubMed

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Neoplasm Recurrence, LocalMajor topic
OvariectomyMajor topic
TamoxifenMajor topic
Age Factors
Aged
Female
Follow-Up Studies
Humans
Middle Aged
Multicenter Studies as Topic
Odds Ratio
Randomized Controlled Trials as Topic
Survival Analysis
Time Factors

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03917082Limited Adjuvant Endocrine Therapy for Low Risk Breast CancerBackground

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections5

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in1346672Adjuvant treatment in breast cancer.https://conductscience.org/library/papers/1346672PubMed
Comment in1346673Adjuvant treatment in breast cancer.https://conductscience.org/library/papers/1346673PubMed
Comment in1346675Adjuvant treatment in breast cancer.https://conductscience.org/library/papers/1346675PubMed
Comment in1346677Adjuvant treatment in breast cancer.https://conductscience.org/library/papers/1346677PubMed
Comment in14575997ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.https://conductscience.org/library/papers/14575997PubMed

Download CSV of comments and corrections

Cited by255

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 358 citations.

PMIDTitleJournalYearIn PapersSource
42171656Evolutionary Antifragile Therapy Is a Treatment Strategy to Suppress Drug Resistance by Exploiting Dose-Response Convexity.Cancer Res2026https://conductscience.org/library/papers/42171656PubMed
41702715Research Waste, Redundancy and the Rise of the Machines: The Questionable Future of Systematic Reviews.Drug Alcohol Rev2026https://conductscience.org/library/papers/41702715PubMed
41634433Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/41634433PubMed
41303742Surgical Ovarian Suppression and Breast Cancer-What Do We Know About It?Medicina (Kaunas)2025https://conductscience.org/library/papers/41303742PubMed
41000654Evolutionary antifragile therapy.bioRxiv2025https://conductscience.org/library/papers/41000654PubMed
40910735Prognostic Performance of the Residual Cancer Burden Index With Respect to Molecular Breast Cancer Subtypes.Eur J Breast Health2025https://conductscience.org/library/papers/40910735PubMed
39850811Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.Front Oncol2024https://conductscience.org/library/papers/39850811PubMed
38912361Vascular Endothelial Growth Factor Expression by Immunohistochemistry as a Possible Indicator of Prognosis in Invasive Breast Carcinoma of No Special Type.Int J Appl Basic Med Res2024https://conductscience.org/library/papers/38912361PubMed
36909339The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/36909339PubMed
34935776Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients.Clin Transl Radiat Oncol2022https://conductscience.org/library/papers/34935776PubMed
34697301Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer.Cell Death Dis2021https://conductscience.org/library/papers/34697301PubMed
34191627Heterogeneity within molecular subtypes of breast cancer.Am J Physiol Cell Physiol2021https://conductscience.org/library/papers/34191627PubMed
33204149Resistance and Overcoming Resistance in Breast Cancer.Breast Cancer (Dove Med Press)2020https://conductscience.org/library/papers/33204149PubMed
32472445Breast cancer: are long-term and intermittent endocrine therapies equally effective?J Cancer Res Clin Oncol2020https://conductscience.org/library/papers/32472445PubMed
32089923Male Breast Cancer: Reevaluate Our Opinion.Case Rep Oncol Med2020https://conductscience.org/library/papers/32089923PubMed
32054043Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.Int J Mol Sci2020https://conductscience.org/library/papers/32054043PubMed
31615089Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis.Cells2019https://conductscience.org/library/papers/31615089PubMed
30840336Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors.Cancer2019https://conductscience.org/library/papers/30840336PubMed
29721484Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant).South Asian J Cancer2018https://conductscience.org/library/papers/29721484PubMed
29312741Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis.J Thorac Dis2017https://conductscience.org/library/papers/29312741PubMed

See all 255 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Authors
  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1345950

GET https://conductscience.org/api/papers/v1/1345950/cited_by?page=2